Clough Capital Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-24,850
Closed -$318K – 129
2025
Q2
$318K Buy
+24,850
New +$306K 0.03% 116
2025
Q1
– Sell
-38,519
Closed -$505K – 124
2024
Q4
$505K Hold
38,519
– – 0.06% 104
2024
Q3
$581K Sell
38,519
-36,110
-48% -$546K 0.06% 110
2024
Q2
$1.06M Sell
74,629
-45,011
-38% -$609K 0.12% 85
2024
Q1
$1.63M Sell
119,640
-255,770
-68% -$3.54M 0.18% 74
2023
Q4
$5.05M Buy
375,410
+244,960
+188% +$3.01M 0.56% 51
2023
Q3
$1.63M Buy
+130,450
New +$1.72M 0.17% 105
2020
Q4
– Sell
-58,926
Closed -$1.04M – 145
2020
Q3
$1.04M Buy
58,926
+19,200
+48% +$344K 0.07% 90
2020
Q2
$713K Buy
+39,726
New +$681K 0.07% 109
2017
Q2
– Sell
-48,545
Closed -$825K – 150
2017
Q1
$825K Hold
48,545
– – 0.05% 109
2016
Q4
$825K Buy
+48,545
New +$852K 0.05% 124
2016
Q3
– Sell
-30,922
Closed -$532K – 196
2016
Q2
$532K Buy
+30,922
New +$571K 0.03% 157
2015
Q4
– Sell
-8,900
Closed -$200K – 211
2015
Q3
$200K Buy
+8,900
New +$249K 0.01% 170

Other funds holding HQL

Clough Capital Partners's HQL Position: Q3 2025 in Review

Clough Capital Partners sold out of abrdn Life Sciences Investors (HQL) in Q3 2025, closing a stake of 24,850 shares — an estimated $318K sold.

Clough Capital Partners first reported a position in HQL in Q3 2015 and held it in 13 quarters. The position peaked at $5.05M in Q4 2023. 85 funds tracked by Wall St. Rank hold HQL as of Q3 2025.

  • Clough Capital Partners reported no remaining abrdn Life Sciences Investors position as of Q3 2025 after selling out during the quarter.
  • Clough Capital Partners sold 24,850 abrdn Life Sciences Investors shares in Q3 2025, an estimated $318K.
  • Clough Capital Partners first reported a position in abrdn Life Sciences Investors in Q3 2015 and held it in 13 quarters.
  • Clough Capital Partners's abrdn Life Sciences Investors position peaked at $5.05M in Q4 2023.
  • 85 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2025.

Based on Clough Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.